In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Albireo Pharma Inc.

www.albireopharma.com

Latest From Albireo Pharma Inc.

Scrip Asks… What Does 2020 Hold For Biopharma? Part 4: The Patient

From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.

Personalized Medicine Artificial Intelligence

US FDA's Stein Outlines Functions Of Rare Disease, Inborn Error Groups In New OND Division

Office of New Drugs director Peter Stein shed some light on how the newly established Division of Rare Diseases and Medical Genetics will operate following the completion of the OND reorganization, drawing mixed reactions from industry speakers.

Leadership FDA

US FDA's Stein To Sponsors: New Leadership From OND Reorganization Won't Change Your Development Plans

Office of New Drugs Director Peter Stein told sponsors during a panel discussion that they will be able to continue agreed upon development programs despite leadership changes arising from the OND reorganization; industry speakers excited, but also have some reservations, about the new OND.

Leadership FDA

NASH Companies Take The Stage At AASLD

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Research and Development Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Hepatic (Liver)
  • Alias(es)
  • Biodel Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Albireo Pharma Inc.
  • Senior Management
  • Ron Cooper, Pres. & CEO
    Simon Harford, CFO
    Patrick Horn, MD, CMO
    Jan Mattsson, PhD, COO
    Pamela Stephenson, Chief Commercial Officer
  • Contact Info
  • Albireo Pharma Inc.
    Phone: (857) 254-5555
    10 Post Office Sq.
    Ste. 502S
    Boston, MA 02109
    USA
UsernamePublicRestriction

Register